Artykuły w czasopismach na temat „BRAFV600E oncogene”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „BRAFV600E oncogene”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Algazi, Alain Patrick, Megan Othus, Benjamin Newell Voorhies, Kari Lynn Kendra, Shaker R. Dakhil, Amy K. Harker-Murray, Christopher D. Lao i in. "Clinical outcomes in patients with BRAFV600 mutant melanoma and undetectable circulating tumor DNA treated with dabrafenib and trametinib." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): 10059. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.10059.
Pełny tekst źródłaRogounovitch, Tatiana I., Svetlana V. Mankovskaya, Mikhail V. Fridman, Tatiana A. Leonova, Victor A. Kondratovitch, Natalya E. Konoplya, Shunichi Yamashita, Norisato Mitsutake i Vladimir A. Saenko. "Major Oncogenic Drivers and Their Clinicopathological Correlations in Sporadic Childhood Papillary Thyroid Carcinoma in Belarus". Cancers 13, nr 13 (5.07.2021): 3374. http://dx.doi.org/10.3390/cancers13133374.
Pełny tekst źródłaPerna, Daniele, Florian A. Karreth, Alistair G. Rust, Pedro A. Perez-Mancera, Mamunur Rashid, Francesco Iorio, Constantine Alifrangis i in. "BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model". Proceedings of the National Academy of Sciences 112, nr 6 (26.01.2015): E536—E545. http://dx.doi.org/10.1073/pnas.1418163112.
Pełny tekst źródłaKaabouch, Meryem, Hafsa Chahdi, Naima Azouzi, Mohammed Oukabli, Issam Rharrassi, Adil Boudhas, Hassan Jaddi i in. "BRAFV600E hot spot mutation in thyroid carcinomas: first Moroccan experience from a single-institution retrospective study". African Health Sciences 20, nr 4 (16.12.2020): 1849–56. http://dx.doi.org/10.4314/ahs.v20i4.40.
Pełny tekst źródłaWang, Liye, Qianyi Lu, Kuikui Jiang, Ruoxi Hong, Shusen Wang i Fei Xu. "BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review". Oncology Research and Treatment 45, nr 1-2 (24.11.2021): 54–61. http://dx.doi.org/10.1159/000520453.
Pełny tekst źródłaZurnadzhy, Liudmyla, Tetiana Bogdanova, Tatiana I. Rogounovitch, Masahiro Ito, Mykola Tronko, Shunichi Yamashita, Norisato Mitsutake, Serhii Chernyshov, Sergii Masiuk i Vladimir A. Saenko. "The BRAFV600E Mutation Is Not a Risk Factor for More Aggressive Tumor Behavior in Radiogenic and Sporadic Papillary Thyroid Carcinoma at a Young Age". Cancers 13, nr 23 (30.11.2021): 6038. http://dx.doi.org/10.3390/cancers13236038.
Pełny tekst źródłaHosier, Gregory W., i Matthew T. Roberts. "Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma". Canadian Urological Association Journal 10, nr 9-10 (13.09.2016): 306. http://dx.doi.org/10.5489/cuaj.3652.
Pełny tekst źródłaChabanet, Tamer Basel, Shannon Steinberg, Peisheng Zhang i Mary Jo Turk. "Elucidating the oncogene-driven regulatory T cell responses during melanoma tumorigenesis." Journal of Immunology 196, nr 1_Supplement (1.05.2016): 74.1. http://dx.doi.org/10.4049/jimmunol.196.supp.74.1.
Pełny tekst źródłaKidger, Andrew M., Linda K. Rushworth, Julia Stellzig, Jane Davidson, Christopher J. Bryant, Cassidy Bayley, Edward Caddye, Tim Rogers, Stephen M. Keyse i Christopher J. Caunt. "Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling". Proceedings of the National Academy of Sciences 114, nr 3 (4.01.2017): E317—E326. http://dx.doi.org/10.1073/pnas.1614684114.
Pełny tekst źródłaSpourquet, Catherine, Ophélie Delcorte, Pascale Lemoine, Nicolas Dauguet, Axelle Loriot, Younes Achouri, Maija Hollmén i in. "BRAFV600E Expression in Thyrocytes Causes Recruitment of Immunosuppressive STABILIN-1 Macrophages". Cancers 14, nr 19 (26.09.2022): 4687. http://dx.doi.org/10.3390/cancers14194687.
Pełny tekst źródłaLee, Min Hee, Seong Eun Lee, Dong Wook Kim, Min Jeong Ryu, Sung Jin Kim, Sung Joong Kim, Yong Kyoung Kim i in. "Mitochondrial Localization and Regulation of BRAFV600E in Thyroid Cancer: A Clinically Used RAF Inhibitor Is Unable to Block the Mitochondrial Activities of BRAFV600E". Journal of Clinical Endocrinology & Metabolism 96, nr 1 (1.01.2011): E19—E30. http://dx.doi.org/10.1210/jc.2010-1071.
Pełny tekst źródłavon Soosten, Laura, Janina Haar, Veronika Frehtman, Stefan Holderbach, Julius Upmeier zu Belzen, Michael Jendrusch, Konstantin Okonechnikov i in. "THER-01. Precision brain tumor therapy by AAV-mediated oncogene editing". Neuro-Oncology 24, Supplement_1 (1.06.2022): i185—i186. http://dx.doi.org/10.1093/neuonc/noac079.695.
Pełny tekst źródłaAdamopoulos, Christos, Kostas A. Papavassiliou, Poulikos I. Poulikakos i Athanasios G. Papavassiliou. "RAF and MEK Inhibitors in Non-Small Cell Lung Cancer". International Journal of Molecular Sciences 25, nr 9 (24.04.2024): 4633. http://dx.doi.org/10.3390/ijms25094633.
Pełny tekst źródłaBaldari, Silvia, Giuliana Di Rocco, Marie C. Heffern, Timothy A. Su, Christopher J. Chang i Gabriele Toietta. "Effects of Copper Chelation on BRAFV600E Positive Colon Carcinoma Cells". Cancers 11, nr 5 (12.05.2019): 659. http://dx.doi.org/10.3390/cancers11050659.
Pełny tekst źródłaJiang, Cuiping, Lin Xie, Yiding Zhang, Masayuki Fujinaga, Wakana Mori, Yusuke Kurihara, Tomoteru Yamasaki, Feng Wang i Ming-Rong Zhang. "Pharmacokinetic Evaluation of [11C]CEP-32496 in Nude Mice Bearing BRAFV600E Mutation-Induced Melanomas". Molecular Imaging 17 (1.01.2018): 153601211879595. http://dx.doi.org/10.1177/1536012118795952.
Pełny tekst źródłaRiesco-Eizaguirre, G., P. Gutiérrez-Martínez, M. A. García-Cabezas, M. Nistal i P. Santisteban. "The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane". Endocrine-Related Cancer 13, nr 1 (marzec 2006): 257–69. http://dx.doi.org/10.1677/erc.1.01119.
Pełny tekst źródłaRecagni, Tassinari, Doria, Cimino-Reale, Zaffaroni, Freccero, Folini i Richter. "The Oncogenic Signaling Pathways in BRAF-Mutant Melanoma Cells are Modulated by Naphthalene Diimide-Like G-Quadruplex Ligands". Cells 8, nr 10 (18.10.2019): 1274. http://dx.doi.org/10.3390/cells8101274.
Pełny tekst źródłaUribe-Alvarez, Cristina, Daniela Araiza-Olivera, Alexa Cannon i Jonathan Chernoff. "Abstract 4747: Novel targets for BRAFV600E and BRAFV600ERAC1P29S drug resistant melanoma". Cancer Research 84, nr 6_Supplement (22.03.2024): 4747. http://dx.doi.org/10.1158/1538-7445.am2024-4747.
Pełny tekst źródłaWongchenko, Matthew J., Antoni Ribas, Paolo A. Ascierto, Brigitte Dréno, Anna Maria di Giacomo, Claus Garbe, Ilsung Chang i in. "Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study". JCO Precision Oncology, nr 2 (listopad 2018): 1–18. http://dx.doi.org/10.1200/po.17.00242.
Pełny tekst źródłaChaft, Jamie E., Scott Swanson, Jay M. Lee, Jules Lin, Hisashi Tsukada, Tianhong Li, R. Taylor Ripley i in. "Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial." Journal of Clinical Oncology 42, nr 16_suppl (1.06.2024): 8068. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.8068.
Pełny tekst źródłaTosios, Konstantinos I., Eleni-Marina Kalogirou i Ioannis G. Koutlas. "Association of MDM2 Overexpression in Ameloblastomas with MDM2 Amplification and BRAFV600E Expression". International Journal of Molecular Sciences 25, nr 4 (13.02.2024): 2238. http://dx.doi.org/10.3390/ijms25042238.
Pełny tekst źródłaStocksdale, Brian, Yaping Joyce Liao, Gwen Coffey i Seema Nagpal. "INNV-06. SECOND GENERATION BRAF/MEK INHIBITION IN ANAPLASTIC PLEOMORPHIC XANTHROASTROCYTOMA". Neuro-Oncology 22, Supplement_2 (listopad 2020): ii117—ii118. http://dx.doi.org/10.1093/neuonc/noaa215.490.
Pełny tekst źródłaDimitrion, Peter, Jugmohit Toor, James Ge, Qiyan Wang, Carl E. Allen, Li Zhou i Qing-Sheng Mi. "HDAC3 Is Required for Pathognomonic Features of Langerhans Cell Histiocytes". Blood 142, Supplement 1 (28.11.2023): 676. http://dx.doi.org/10.1182/blood-2023-185195.
Pełny tekst źródłaCangi, Maria Giulia, Riccardo Biavasco, Giulio Cavalli, Greta Grassini, Elena Dal-Cin, Corrado Campochiaro, Barbara Guglielmi i in. "BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease". Annals of the Rheumatic Diseases 74, nr 8 (26.03.2014): 1596–602. http://dx.doi.org/10.1136/annrheumdis-2013-204924.
Pełny tekst źródłaHassan, Alaa A., Nasr K. Mohamed, Ashraf A. Aly, Mohamed Ramadan, Hesham A. M. Gomaa, Ahmed T. Abdel-Aziz, Bahaa G. M. Youssif, Stefan Bräse i Olaf Fuhr. "Synthesis and Antiproliferative Potential of Thiazole and 4-Thiazolidinone Containing Motifs as Dual Inhibitors of EGFR and BRAFV600E". Molecules 28, nr 24 (5.12.2023): 7951. http://dx.doi.org/10.3390/molecules28247951.
Pełny tekst źródłaSigaud, Romain, Florian Selt, Thomas Hielscher, Nina Overbeck, Diren Usta, Marc Remke, Daniel Picard i in. "LGG-14. MULTI-OMIC ANALYSIS OF MAPK ACTIVATION IN PEDIATRIC PILOCYTIC ASTROCYTOMA". Neuro-Oncology 22, Supplement_3 (1.12.2020): iii368. http://dx.doi.org/10.1093/neuonc/noaa222.396.
Pełny tekst źródłaGrob, Sydney, Lianna Nobre, Kurtis Davies, Scott Ryall, Dara Aisner, Lindsey Hoffman, Shadi Zahedi i in. "LGG-34. CLINICAL AND MOLECULAR CHARACTERIZATION OF A MULTI-INSTITUTIONAL COHORT OF PEDIATRIC SPINAL CORD LOW-GRADE GLIOMAS". Neuro-Oncology 22, Supplement_3 (1.12.2020): iii373. http://dx.doi.org/10.1093/neuonc/noaa222.416.
Pełny tekst źródłaSadangi, Shreyans, Katarina Milosavljevic, Edgardo Castro-Perez, Marcos Lares, Mithalesh Singh, Sarah Altameemi, David J. Beebe, Jose M. Ayuso i Vijayasaradhi Setaluri. "Role of the Skin Microenvironment in Melanomagenesis: Epidermal Keratinocytes and Dermal Fibroblasts Promote BRAF Oncogene-Induced Senescence Escape in Melanocytes". Cancers 14, nr 5 (27.02.2022): 1233. http://dx.doi.org/10.3390/cancers14051233.
Pełny tekst źródłaAlaali, Lujain A., Ming Yuan, Chales Eberhart i Eric Raabe. "Abstract 3414: The pan-RAF inhibitor tovorafenib suppresses NF1-mutant glioma through upregulation of FOXO1 and triggering of oncogene-induced senescence". Cancer Research 83, nr 7_Supplement (4.04.2023): 3414. http://dx.doi.org/10.1158/1538-7445.am2023-3414.
Pełny tekst źródłaAlaali, Lujain, Eric Raabe, Micah Maxwell, Charles Eberhart i Hui Zhang. "DDDR-18. COMPREHENSIVE PROTEOMIC PROFILING OF BRAFV600E GLIOMA CELLS SHOWS UPREGULATION OF GLYCOLYSIS AND TCA CYCLE PROTEINS AFTER COMBINED MTOR AND MAP KINASE PATHWAY BLOCKADE". Neuro-Oncology 24, Supplement_7 (1.11.2022): vii102. http://dx.doi.org/10.1093/neuonc/noac209.383.
Pełny tekst źródłaTemprine, Kelsey, Nathaniel R. Campbell, Richard Huang, Erin M. Langdon, Theresa Simon-Vermot, Krisha Mehta, Averill Clapp, Mollie Chipman i Richard M. White. "Regulation of the error-prone DNA polymerase Polκ by oncogenic signaling and its contribution to drug resistance". Science Signaling 13, nr 629 (28.04.2020): eaau1453. http://dx.doi.org/10.1126/scisignal.aau1453.
Pełny tekst źródłaSong, Kai, Jenna K. Minami, Arthur Huang, Siavash R. Dehkordi, Shirley H. Lomeli, Jens Luebeck, Mark H. Goodman i in. "Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges". Cancer Discovery 12, nr 4 (20.12.2021): 1046–69. http://dx.doi.org/10.1158/2159-8290.cd-20-0936.
Pełny tekst źródłaCorso, Giovanni, Valeria Pascale, Giuseppe Flauti, Daniele Marrelli i Franco Roviello. "Oncogenic mutations in colorectal cancer, indications for anatomical sites, and targeted intervention." Journal of Clinical Oncology 31, nr 15_suppl (20.05.2013): e22037-e22037. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e22037.
Pełny tekst źródłaNgiow, Shin Foong, Katrina M. Meeth, Kimberley Stannard, Deborah S. Barkauskas, Gideon Bollag, Marcus Bosenberg i Mark J. Smyth. "Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma". OncoImmunology 5, nr 3 (10.12.2015): e1089381. http://dx.doi.org/10.1080/2162402x.2015.1089381.
Pełny tekst źródłaLuciano, Angelo, Luigi Liguori, Giovanna Polcaro, Francesco Sabbatino i Stefano Pepe. "Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Case Report and a Narrative Review". Clinics and Practice 13, nr 6 (30.11.2023): 1549–60. http://dx.doi.org/10.3390/clinpract13060136.
Pełny tekst źródłaDrilon, Alexander E., Melissa Lynne Johnson, Shirish M. Gadgeel, Dale Nepert, Gang Feng, Marzieh Golmakani, Micaela Reddy i in. "A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors." Journal of Clinical Oncology 41, nr 16_suppl (1.06.2023): 3020. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3020.
Pełny tekst źródłaRobb, Ryan, Linlin Yang, Changxian Shen, Adam R. Wolfe, Amy Webb, Xiaoli Zhang, Marall Vedaie i in. "Inhibiting BRAF Oncogene–Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair". Clinical Cancer Research 25, nr 15 (16.05.2019): 4749–60. http://dx.doi.org/10.1158/1078-0432.ccr-18-3625.
Pełny tekst źródłaAlotaibi, Sultan, Osama Alhafi, Hatem Nasr, Khalid Eltayeb i Ghaleb Elyamany. "Erdheim-Chester Disease: Case Report with Aggressive Multisystem Manifestations and Review of the Literature". Case Reports in Oncology 10, nr 2 (14.06.2017): 501–7. http://dx.doi.org/10.1159/000477336.
Pełny tekst źródłaDawar, Richa, Kunal Gawri, Estelamari Rodriguez, Deukwoo Kwon, Fahmin Basher, Philippos Apolinario Costa, Khadeja Khan, Tisdrey Torres, Chukwuemeka Ikpeazu i Gilberto Lopes. "Clinical attributes and outcomes in metastatic non-small cell lung cancer bearing BRAF mutations treated with targeted therapy versus immunotherapy." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): e21219-e21219. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e21219.
Pełny tekst źródłaGeisen, Mariah, Josiane weber-Tessmann, Courtney Kelson, Daheng He, Chi Wang, Abu Saleh Mosa Faisal, Jill Kolesar i Yekaterina Zaytseva. "Abstract 4760: Inhibition of FASN postpones development of resistance to BRAF inhibitors in colorectal cancer". Cancer Research 84, nr 6_Supplement (22.03.2024): 4760. http://dx.doi.org/10.1158/1538-7445.am2024-4760.
Pełny tekst źródłaRiesco-Eizaguirre, Garcilaso, Irene Rodríguez, Antonio De la Vieja, Eugenia Costamagna, Nancy Carrasco, Manuel Nistal i Pilar Santisteban. "The BRAFV600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer". Cancer Research 69, nr 21 (27.10.2009): 8317–25. http://dx.doi.org/10.1158/0008-5472.can-09-1248.
Pełny tekst źródłaSchott, M. "The BRAFV600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer". Yearbook of Endocrinology 2010 (styczeń 2010): 154–55. http://dx.doi.org/10.1016/s0084-3741(10)79511-1.
Pełny tekst źródłaPricl, Sabrina, Erik Laurini, Domenico Marson i Gabriele Cavalieri. "Abstract C153: Rare BRAF mutations in menlanoma and beyond: Rationalizing the afficacy of B-raf inhibitors via HPC-based in silico/in vitro investigations". Molecular Cancer Therapeutics 22, nr 12_Supplement (1.12.2023): C153. http://dx.doi.org/10.1158/1535-7163.targ-23-c153.
Pełny tekst źródłaLim, Kee Siang, Zachary Wei Ern Yong, Huajing Wang, Tuan Zea Tan, Ruby Yun-Ju Huang, Daisuke Yamamoto, Noriyuki Inaki i in. "Inflammatory and mitogenic signals drive interleukin 23 subunit alpha (IL23A) secretion independent of IL12B in intestinal epithelial cells". Journal of Biological Chemistry 295, nr 19 (24.03.2020): 6387–400. http://dx.doi.org/10.1074/jbc.ra120.012943.
Pełny tekst źródłaChan, Lai N., Christian Hurtz, Huimin Geng, Franziska Auer, Zhengshan Chen, Gang Xiao, Jae-Woong Lee, Kadriye Nehir Cosgun, B. Hilda Ye i Markus Muschen. "Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling". Blood 132, Supplement 1 (29.11.2018): 1336. http://dx.doi.org/10.1182/blood-2018-99-115514.
Pełny tekst źródłaLiebig, Janika K., Silke Kuphal i Anja Katrin Bosserhoff. "HuRdling Senescence: HuR Breaks BRAF-Induced Senescence in Melanocytes and Supports Melanoma Growth". Cancers 12, nr 5 (21.05.2020): 1299. http://dx.doi.org/10.3390/cancers12051299.
Pełny tekst źródłaKunz, Manfred, i Julio Vera. "Modelling of Protein Kinase Signaling Pathways in Melanoma and Other Cancers". Cancers 11, nr 4 (3.04.2019): 465. http://dx.doi.org/10.3390/cancers11040465.
Pełny tekst źródłaGroisberg, Roman, David S. Hong, Filip Janku, Yunfang Jiang, ChongJuan Wei, Daniel D. Karp, Apostolia Maria Tsimberidou i in. "SWI/SNF complex subunit aberrations in diverse cancers: Next-generation sequencing of 539 patients." Journal of Clinical Oncology 35, nr 15_suppl (20.05.2017): 2588. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.2588.
Pełny tekst źródłaBorgenvik, Anna, Sean Misek, Alexander Zhang, Ruth Fekade, Timothy Ragnoni, Aaron Fultineer, Kevin Zhou i in. "LGG-29. BEYOND MAPK SIGNALING - GENOME-SCALE CRISPR/CAS9 SCREENS REVEAL NEW TARGETS FOR TREATMENT OF KIAA1549::BRAF-DRIVEN PEDIATRIC LOW-GRADE GLIOMA". Neuro-Oncology 26, Supplement_4 (18.06.2024): 0. http://dx.doi.org/10.1093/neuonc/noae064.422.
Pełny tekst źródłaLee, Joon-Hyop, Jiyoung Ahn, Won Seo Park, Eun Kyung Choe, Eunyoung Kim, Rumi Shin, Seung Chul Heo i in. "Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study". Journal of Clinical Medicine 8, nr 1 (17.01.2019): 111. http://dx.doi.org/10.3390/jcm8010111.
Pełny tekst źródła